Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma von SENZER, Neil N, KAUFMAN, Howard L, GOLDSWEIG, Howard, MARSHALL, Tracey, LOVE, Colin, COFFIN, Robert, NEMUNAITIS, John J, AMATRUDA, Thomas, NEMUNAITIS, Mike, REID, Tony, DANIELS, Gregory, GONZALEZ, Rene, GLASPY, John, WHITMAN, Eric, HARRINGTON, Kevin

Volltext

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the He... von SOULIERES, Denis, SENZER, Neil N, VOKES, Everett E, HIDALGO, Manuel, AGARWALA, Sanjiv S, SIU, Lillian L

Volltext

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma von Eager, Robert M, Cunningham, C Casey, Senzer, Neil N, Stephenson, Jr, Joe, Anthony, Stephen P, O'Day, Steven J, Frenette, Gary, Pavlick, Anna C, Jones, Barry, Uprichard, Margaret, Nemunaitis, John

Volltext

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer von SEQUIST, Lecia V, GETTINGER, Scott, SWEENEY, Jennifer, WALKER, John R, FRITZ, Christian, ROSS, Robert W, GRAYZEL, David, ENGELMAN, Jeffrey A, BORGER, Darrell R, PAEZ, Guillermo, NATALE, Ronald, SENZER, Neil N, MARTINS, Renato G, JÄNNE, Pasi A, LILENBAUM, Rogerio, GRAY, Jhanelle E, IAFRATE, A. John, KATAYAMA, Ryohei, HAFEEZ, Nafeeza

Volltext

MicroRNA profile analysis of human prostate cancers von Tong, A W, Fulgham, P, Jay, C, Chen, P, Khalil, I, Liu, S, Senzer, N, Eklund, A C, Han, J, Nemunaitis, J

Volltext

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis von Santoro, A, Simonelli, M, Rodriguez-Lope, C, Zucali, P, Camacho, L H, Granito, A, Senzer, N, Rimassa, L, Abbadessa, G, Schwartz, B, Lamar, M, Savage, R E, Bruix, J

Volltext

Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development von Rao, D D, Senzer, N, Cleary, M A, Nemunaitis, J

Volltext

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours von Bowles, D W, Ma, W W, Senzer, N, Brahmer, J R, Adjei, A A, Davies, M, Lazar, A J, Vo, A, Peterson, S, Walker, L, Hausman, D, Rudin, C M, Jimeno, A

Volltext

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients von Nemunaitis, J, Nemunaitis, M, Senzer, N, Snitz, P, Bedell, C, Kumar, P, Pappen, B, Maples, P B, Shawler, D, Fakhrai, H

Volltext

Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer von Eager, R.M, Cunningham, C.C, Senzer, N, Richards, D.A, Raju, R.N, Jones, B, Uprichard, M, Nemunaitis, J

Volltext

Prostate cancer: Multimodality approaches with docetaxel von Senzer, Neil N

Volltext

Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial von Epstein, J B, Silverman, Jr, S, Paggiarino, D A, Crockett, S, Schubert, M M, Senzer, N N, Lockhart, P B, Gallagher, M J, Peterson, D E, Leveque, F G

Volltext

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients von Nemunaitis, J, Senzer, N, Sarmiento, S, Zhang, Y-A, Arzaga, R, Sands, B, Maples, P, Tong, A W

Volltext

Transcription factors: their potential as targets for an individualized therapeutic approach to cancer von Mees, C, Nemunaitis, J, Senzer, N

Volltext

Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform von Wu, J, Liu, S, Yu, J, Zhou, G, Rao, D, Jay, C M, Kumar, P, Sanchez, R, Templeton, N, Senzer, N, Maples, P, Nemunaitis, J, Brunicardi, F C

Volltext

Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: Preliminary results von Barve, M, Grosen, E.A, Fine, B.A, Heffernan, T.P, Matthews, C.M, Stringer, C.A, Koon, E.C, Goodman, H.M, Fleming, E.L, DeMars, L.R, Bergman, M.S, Senzer, N, Nemunaitis, J

Volltext

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities von MESSERSMITH, Wells A, LAHERU, Daniel A, SENZER, Neil N, DONEHOWER, Ross C, GROULEFF, Paula, ROGERS, Theresa, KELLEY, Sean K, RAMIES, David A, LUM, Bert L, HIDALGO, Manuel

Volltext

Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine von Nemunaitis, J, Senzer, N, Olivares, J, Kumar, P, Barve, M, Kuhn, J, Nemunaitis, T, Magee, M, Yu, Y, Wallraven, G, Pappen, B O, Maples, P B

Volltext

Immune response and survival of refractory cancer patients who received TGF- beta 2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine von Nemunaitis, J, Senzer, N, Olivares, J, Kumar, P, Barve, M, Kuhn, J, Nemunaitis, T, Magee, M, Yu, Y, Wallraven, G, Pappen, B O, Maples, P B

Volltext

Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy... von LOESCH, David, GRECO, F. Anthony, PIPPEN, John, LINDQUIST, Deborah, MCINTYRE, Kristi, BLUM, Joanne L, MODIANO, Manuel R, BOEHM, Kristi A, FENG ZHAN, ASMAR, Lina, ROBERT, Nicholas, SENZER, Neil N, BURRIS, Howard A, HAINSWORTH, John D, JONES, Stephen, VUKELJA, Svetislava J, SANDBACH, John, HOLMES, Frankie, SEDLACEK, Scot

Volltext